# A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants

> **NCT06752174** · PHASE3 · COMPLETED · sponsor: **Beijing Minhai Biotechnology Co., Ltd** · enrollment: 300 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** sIPV+bOPV
- **BIOLOGICAL:** wIPV+bOPV

## Key facts

- **NCT ID:** NCT06752174
- **Lead sponsor:** Beijing Minhai Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-08
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752174, "A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06752174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*